Departments of Microbiology, Immunology, and Cancer Biology, Virginia, USA.
Lab Chip. 2019 Mar 27;19(7):1193-1204. doi: 10.1039/c8lc00755a.
The development of drugs to treat cancer is hampered by the inefficiency of translating pre-clinical in vitro monoculture and mouse studies into clinical benefit. There is a critical need to improve the accuracy of evaluating pre-clinical drug efficacy through the development of more physiologically relevant models. In this study, a human triculture 3D in vitro tumor microenvironment system (TMES) was engineered to accurately mimic the tumor microenvironment. The TMES recapitulates tumor hemodynamics and biological transport with co-cultured human microvascular endothelial cells, pancreatic ductal adenocarcinoma, and pancreatic stellate cells. We demonstrate that significant tumor cell transcriptomic changes occur in the TMES that correlate with the in vivo xenograft and patient transcriptome. Treatment with therapeutically relevant doses of chemotherapeutics yields responses paralleling the patients' clinical responses. Thus, this model provides a unique platform to rigorously evaluate novel therapies and is amenable to using patient tumor material directly, with applicability for patient avatars.
癌症治疗药物的开发受到将临床前体外单细胞培养和小鼠研究转化为临床获益的效率低下的阻碍。迫切需要通过开发更具生理相关性的模型来提高评估临床前药物疗效的准确性。在这项研究中,构建了一种人类三培养 3D 体外肿瘤微环境系统(TMES),以准确模拟肿瘤微环境。该 TMES 通过共培养人微血管内皮细胞、胰腺导管腺癌和胰腺星状细胞来重现肿瘤血液动力学和生物转运。我们证明,TMES 中发生了显著的肿瘤细胞转录组变化,与体内异种移植和患者转录组相关。用治疗相关剂量的化疗药物治疗会产生与患者临床反应相平行的反应。因此,该模型为严格评估新疗法提供了一个独特的平台,并且可以直接使用患者的肿瘤材料,适用于患者替身。